Nitika Pharma Unveils Microcrystalline Cellulose Manufacturing Plant in Nagpur
The newly inaugurated plant in Nagpur is equipped with advanced technology and infrastructure having an installed capacity of 1200 MT.
Maharashtra-based Nitika Pharmaceuticals Specialities, a manufacturer of excipients, has unveiled its microcrystalline cellulose (*Tabcell) manufacturing plant at Butibori, Nagpur.
The newly inaugurated plant in Nagpur is equipped with advanced technology and infrastructure having an installed capacity of 1200 MT.
With this inauguration, this company has achieved the position of the largest microcrystalline cellulose manufacturing facility in the country. Further, it is the only excipient manufacturing company to receive the Production Linked Incentive (PLI) scheme from the Government of India
The manufacturing plan inaugural ceremony was attended by Minister of Road Transport and Highways India, Nitin Gadkari.
Reportedly, the pharmaceutical company manufactures the excipients of international standards in India while exporting the same in more than 92 countries worldwide.
Looking forward, the company aims to set up two more plants which are expected to generate more than 750 employment in the next two years.
Established in 1991, Nitika Pharmaceuticals is dedicated to implementing sound manufacturing and laboratory practices. Their objective is to ensure that the current and future well-being of the company and its employees is contingent upon the quality and integrity of their pharmaceutical and chemical products.
While it is the only excipient manufacturing company to receive the PLI scheme from the Government of India; several other Indian Pharmaceutical companies have also been selected as beneficiaries of the scheme.
Names include Sun Pharmaceutical Industries Ltd, Aurobindo Pharma Ltd, Dr Reddy's Laboratories Ltd, Lupin Ltd, Mylan Laboratories Ltd, Cadila Healthcare Ltd, Cipla Ltd, Amneal Pharmaceuticals Pvt Ltd, Glenmark Pharmaceuticals Ltd, and Neogen Chemicals Ltd.
The PLI scheme of the Government of India is a performance-linked incentive to give companies incentives on incremental sales from products manufactured in domestic units.
It aims to encourage the pharmaceutical industry, to enhance its manufacturing capabilities, diversify the product portfolio with a focus on complex generics, improve patented drugs, elevate the value chain, and for attracting investments.
